RU 58841

RU 58841

RU 58841Dermatology
CAS: 154992-24-2
MF: C17H18F3N3O3
MW: 369.34
Indications
Acne Vulgaris
Therapeutic Target
AR
Usage

An androgen receptor antagonist that promotes hair regrowth.

Specification
>99%
Product Description

Overview

RU 58841 is an effective topical non-steroidal androgen receptor antagonist with specific anti-androgenic effects. It can be used in pharmaceutical research related to abnormal androgen-related diseases such as androgenetic alopecia, benign prostatic hyperplasia, acne and androgen-dependent skin diseases.

Synonyms: PSK-3841; HMR-3841

EINECS: 1592732-453-0

Product Categories: Androgen receptor; Endocrine; Organic Compounds; Aromatics; Pharmaceuticals; Intermediates & Fine Chemicals; API

Mol File: 154992-24-2.mol

Physicochemical Properties

Boiling point: 493.6°C at 760 mmHg

Density: 1.39g/cm3

Storage temp: -20℃

Form: Solid

Color: White to Off-white

MSDS Information

Experimental Data

1.Cell Experiment

Solubility in DMSO: ≥100 mg/mL (270.75 mM; Hygroscopic DMSO can significantly affect product solubility, so use freshly opened DMSO.)

* "≥" means soluble, but saturation is unknown.

Preparing Stock Solutions:

image

Prepare a stock solution in an appropriate solvent based on the product's solubility in different solvents. Once prepared, aliquot and store to avoid product loss due to repeated freeze-thaw cycles.

Stock solution storage and expiration date: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, use within 2 years; when stored at -20°C, use within 1 year.


2.Animal Experiment

For the following dissolution protocols, first prepare a clear stock solution in vitro, then add cosolvents in sequence:


—To ensure reliable experimental results, the clear stock solution can be stored appropriately according to storage conditions. For in vivo experiments, it is recommended that the working solution be prepared fresh and used the same day.

The percentages shown before the solvents below refer to the volume percentage of the solvent in the final solution. If precipitation or precipitation occurs during the preparation process, heating and/or sonication can be used to aid dissolution.


Protocol 1

Add each solvent in order: 10% DMSO, 40% PEG300, 5% Tween-80, 45% Saline.

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear Solution

This protocol produces a clear solution of ≥ 2.5 mg/mL (saturation unknown).

For a 1 mL working solution, add 100 μL of the 25.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix thoroughly. Add 50 μL of Tween-80 to the solution and mix thoroughly. Then, add 450 μL of normal saline to bring the volume to 1 mL.

To prepare normal saline, dissolve 0.9 g of sodium chloride in ddH₂O and dilute to 100 mL. This will yield a clear, transparent normal saline solution.


Protocol 2

Add each solvent in sequence: 10% DMSO, 90% (20% SBE-β-CD in saline)

Solubility: ≥2.5 mg/mL (6.77 mM); Clear Solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

For a 1 mL working solution, add 100 μL of the 25.0 mg/mL clear DMSO stock solution to 900 μL of a 20% SBE-β-CD solution in saline and mix thoroughly.

Dissolve 2 g of SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder in 10 mL of saline until clear and transparent.


Protocol 3

Please add each solvent in the following order: 10% DMSO, 90% corn oil.

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol produces a clear solution of ≥ 2.5 mg/mL (saturation unknown). This protocol should be used for animal experiments with experimental durations exceeding two weeks.

For a 1 mL working solution, add 100 μL of the 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix thoroughly.

Pharmacodynamics

Mechanism Of Action